PCT/UA94/00694

IN THE CLAIMS:


Please cancel claims 1-13, without prejudice, and add the following new claims:

-14. A method of preventing or controlling cataract or eataract-like disorders in the eye of a mammalian subject which comprises the step of administrating to the subject an effective amount of one or more inhibitors of TGFB.--

--15. The method according to claim 14 wherein the one or more inhibitors of TGFB are selected from proteins, gycloproteins and proteoglycans.--

--16. The method according to claim 15 wherein the protein inhibitors of TGFB are selected from antibodies and peptide growth factors.--

- --17. The method according to claim 15 wherein the glycoprotein inhibitors of TGFB are selected from α_2 -macroglobulin, laminin and collagen.--
- --18. The method according to claim 15 wherein the proteoglycan inhibitors of TGFB are selected from decorin, heparan sulfate proteoglycans and biglycan.--
- --19. An ophthalmological formulation comprising one or more inhibitors of TGFß in an ophthalmologically acceptable carrier but excluding conventional pharmaceutically acceptable carriers.--
- --20. The ophthalmological formulation according to claim 19 wherein the one or more inhibitors of TGFß are selected from proteins, glycoproteins and proteoglycans.--



- --21. The ophthalmological formulation according to claim 20 wherein the protein inhibitors of TGFB are selected from antibodies and peptide growth factors.--
- --22. The ophthalmological formulation according to claim 20 wherein the glycoprotein inhibitors of TGFB are selected from α_2 -macroglobulin, laminin and collagen.--
- --23. The ophthalmological formulation according to claim 20 wherein the proteoglycan inhibitors of TGFß are selected from decorin, heparan sulfate proteoglycans and biglycan.--
- --24. A method of preventing or controlling aftercataract formation in the eye of a maximalian subject following lens implant surgery which comprises the step of implanting in the eye of the subject a lens coated with one or more TGFB inhibitors.--
- --25. The method according to claim 24 wherein the one or more inhibitors of TGFß are selected from proteins, glycoproteins and proteoglycans.--
- --26. The method according to claim 25 wherein the protein inhibitors of TGFß are selected from antibodies and peptide growth factors.--
- --27. The method according to claim 25 wherein the glycoprotein inhibitors of TGFB are selected from α_2 -macroglobulin, laminin and collagen.--
- --28. The method according to claim 25 wherein the proteoglycan inhibitors of TGFB are selected from decorin, heparan sulfate proteoglycans and biglycan.--

PCT/UA94/00694

- --29. A lens implant comprising a coating, the coating including one or more TGFB inhibitors.--
- --30. The lens implant according to claim 29 coated with one or more TGFB inhibitors selected from proteins, glycoproteins and proteoglycans.--
- --31. The lens implant according to claim 30 wherein the protein inhibitors of TGFB /are selected from antibodies and peptide growth factors.--
- --32. The lens implant according to claim 30 wherein the glycoprotein inhibitors of TGFB are selected from α_2 -macroglobulin, laminin and collagen.--
- --33. The lens implant according to claim 30 wherein the proteoglycan inhibitors of TGFB are selected from decorin, heparan sulfate proteoglycans and biglycan.--

--34. The use of inhibitors of TGFB in the manufacture and ophthalmological formulation for preventing or controlling cataract or cataract-like disorders.--